The Global Intravenous Equipment market was valued at more than USD 16.72 Billion in 2025, and expected to reach a market size of more than USD 23.99 Billion by 2031 with the CAGR
The IV infusion equipment market covers the global market for devices and products specially designed to administer fluids, medications, or therapeutic agents via veins in a patient's body. These devices are of great importance in a wide range of healthcare settings, from hospitals to medical centers and health services at home. The market for IV infusion equipment covering a broad range of instruments and products to administer liquids, medications or treatments directly in the patient's vein is an important part of the worldwide healthcare industry. In a variety of healthcare settings, including hospitals, doctor's offices, rehabilitation centers and home care which serve all age groups and illnesses, this market has an important role. These devices are used to monitor the rate and volume of fluids or medicinal products delivered through an IV so as to be sure that they are administered accurately and precisely. They are especially important for patients requiring periodic infusion therapy in the intensive care units, surgery settings and to patients with continuous infusion therapy. The increasing prevalence of chronic diseases, such as cardiovascular disorders, cancer, and diabetes, has led to a rise in the demand for IV therapies. In addition, access to health services has been increased and IV equipment is used more widely in developing countries due to the development of healthcare infrastructure. According to the research report "Global Intravenous Equipment Market Outlook, 2031," published by Bonafide Research, the Global Intravenous Equipment market was valued at more than USD 16.72 Billion in 2025, and expected to reach a market size of more than USD 23.99 Billion by 2031 with the CAGR of 6.37% from 2026-2031. Recent strategic acquisitions highlight market expansion BD acquired Edwards Lifesciences critical care assets for 4.2 billion dollars to integrate monitoring with infusion delivery while Strykers 4.9 billion dollar purchase of Inari Medical secures its entry into peripheral vascular infusion therapies signaling an expansion beyond traditional orthopedics. Regulatory stringency raises operating thresholds, and smaller firms like InfuTronix exited the market after recalling 52,328 Nimbus units, highlighting the financial risks associated with quality lapses. Platform strategies that integrate infusion pumps, disposables, and analytics create sticky ecosystems that increase switching costs for healthcare providers, and strengthen customer loyalty. AI capabilities have emerged as key competitive differentiators, with BD’s HemoSphere Alta offering real time cerebral autoregulatory insights, and Baxter enhancing its Spectrum IQ system with dose change alerts and remote monitoring features. White space opportunities remain significant in home infusion monitoring and mid tier emerging markets, where optimized systems cost can provide effective alternatives to premium devices while maintaining safety and efficiency. Cybersecurity compliance and software as a medical device expertise are becoming essential requirements for new entrants, as connected infusion systems grow in adoption. Globally, the IV therapy devices market is experiencing increased competition driven by technological innovation, rising demand for outpatient and home based therapy, and the need for enhanced patient safety and infection control.
to Download this information in a PDF
A Bonafide Research industry report provides in-depth market analysis, trends, competitive insights, and strategic recommendations to help businesses make informed decisions.
Download SampleMarket Drivers • Rising prevalence of chronic diseases: One of the primary drivers of the global intravenous equipment market is the rising prevalence of chronic diseases such as cancer, diabetes, cardiovascular disorders, and kidney diseases, along with the increasing number of surgical procedures worldwide. Patients with these conditions often require long-term intravenous therapy for medication delivery, fluid replacement, parenteral nutrition, and blood transfusions. As the global population ages and the incidence of chronic illnesses grows, hospitals, clinics, and homecare providers are investing more heavily in advanced intravenous equipment, including infusion pumps, catheters, and safety devices, to ensure effective, precise, and safe therapy. • Technological advancements: Another significant driver is the rapid technological advancement in IV equipment, including smart infusion pumps, integrated closed systems, needleless connectors, and AI-enabled monitoring features. These innovations enhance patient safety by reducing medication errors, infection risks, and needlestick injuries. Integration with electronic health records and remote monitoring systems allows real-time tracking of infusion therapy, improving workflow efficiency for healthcare professionals and supporting personalized care. Market Challenges • High cost of advanced IV devices: Despite growing demand, the high cost of sophisticated intravenous equipment and ongoing maintenance requirements pose a challenge for widespread adoption, especially in emerging markets. Advanced devices such as smart infusion pumps and integrated closed systems require significant upfront investment, specialized training for staff, and periodic calibration or maintenance to ensure accuracy and safety. In regions with limited healthcare budgets or insufficient trained personnel, cost constraints can delay adoption and reduce market penetration, particularly in small clinics, rural hospitals, and homecare settings. • Regulatory complexities: The global market also faces challenges related to regulatory complexities and differences in standards across countries. Manufacturers must comply with multiple regulatory frameworks, including FDA regulations in the US, CE marking in Europe, and other national approvals in Asia, Latin America, and the Middle East. These requirements involve extensive clinical testing, documentation, and quality management system compliance, which can delay product launches, increase costs, and create barriers for new entrants in the market. Market Trends • Shift toward homecare IV therapy: A prominent trend is the increasing adoption of IV therapy in homecare and ambulatory settings. Portable infusion pumps, prefilled syringes, and closed system devices are being designed for safe and convenient use outside hospitals, responding to patient demand for flexible care options, reduced hospital stays, and cost-effective treatment models. • Focus on safety and infection control: Another trend is the rising emphasis on patient safety, infection prevention, and compliance with international standards. Devices like needleless connectors, retractable needles, and integrated closed systems are gaining popularity to minimize contamination and needlestick injuries, reflecting a broader industry commitment to safer intravenous practices.
| By Product | IV Catheters | |
| Infusion Pumps | ||
| Administration Sets | ||
| Securement Devices | ||
| Needless Connectors | ||
| Stopcocks and Check Valves | ||
| Drip Chambers | ||
| Others | ||
| By End User | Hospital | |
| Clinics | ||
| Home Care Settings | ||
| Others | ||
| By Indication | Cardiovascular Disorders & Hypertension | |
| Pregnancy | ||
| Diabetes | ||
| Respiratory Diseases | ||
| Cancer | ||
| Movement Disorders | ||
| Hearing Disorders | ||
| Wound Care | ||
| Other Indication (sleep disorders, kidney disorders, neurovascular diseases, and HIV) | ||
| By Product Type | IV Catheters | |
| IV Infusion Pumps | ||
| IV Securement Devices | ||
| IV Administration Sets & Solutions | ||
| IV Needles & Syringes | ||
| Stopcocks & Check Valves | ||
| Others | ||
| By Application | Hospitals & Clinics/Dialysis Centers | |
| Ambulatory Surgical Centers (ASCs) | ||
| Home Care Settings | ||
| Others | ||
| By Technology | Conventional IV Devices | |
| Safety IV Devices (Needleless, retractable needles - driven by needlestick injury prevention regulations) | ||
| Integrated/Closed Systems | ||
| Geography | North America | United States |
| Canada | ||
| Mexico | ||
| Europe | Germany | |
| United Kingdom | ||
| France | ||
| Italy | ||
| Spain | ||
| Russia | ||
| Asia-Pacific | China | |
| Japan | ||
| India | ||
| Australia | ||
| South Korea | ||
| South America | Brazil | |
| Argentina | ||
| Colombia | ||
| MEA | United Arab Emirates | |
| Saudi Arabia | ||
| South Africa | ||
IV catheters dominate the global intravenous equipment market due to their essential role in enabling vascular access for a wide range of clinical therapies and their widespread use across hospitals and homecare settings. IV catheters are indispensable in virtually every healthcare setting, from emergency care and intensive care units to oncology, dialysis, and general wards, making them the most frequently used intravenous product type. Hospitals, which account for the largest portion of intravenous equipment utilization, rely heavily on catheters for short term and long term vascular access, as patients often require multiple infusions simultaneously or sequentially, necessitating the use of high quality, reliable catheters to ensure treatment efficacy and patient safety. The widespread prevalence of chronic diseases such as cancer, cardiovascular disorders, diabetes, and kidney disease has significantly contributed to the demand for IV catheters, as these conditions often require repeated or continuous intravenous therapy over extended periods. Additionally, the rise in surgical procedures and critical care interventions worldwide further increases the need for dependable vascular access, positioning IV catheters as a central component of hospital operations and patient management. Safety concerns and infection prevention also reinforce the demand for advanced catheter technologies, including needleless connectors, antimicrobial coated catheters, and closed system designs that minimize contamination risk and reduce the incidence of catheter associated bloodstream infections. Technological advancements in catheter design, materials, and insertion techniques have improved patient comfort, reduced complications, and enhanced overall clinical outcomes, encouraging healthcare providers to adopt premium and specialized catheter products. Hospitals and clinics including dialysis centers are the largest application segment in the global intravenous equipment market because they provide the infrastructure and patient volume necessary for continuous therapy. Hospitals and clinics including dialysis centers dominate the global intravenous equipment market as the primary end users due to their central role in delivering intravenous therapies across a wide spectrum of medical conditions. These healthcare facilities manage acute, chronic, and critical care cases that require precise administration of fluids, medications, blood transfusions, and nutritional support, often simultaneously across multiple departments such as intensive care units, emergency rooms, surgical suites, oncology wards, and general wards. The high patient turnover and complexity of treatments in hospitals ensure a consistent and substantial demand for intravenous equipment including infusion pumps, catheters, administration sets, securement devices, and safety systems, which are essential for maintaining clinical accuracy, preventing infections, and improving patient outcomes. Dialysis centers embedded within hospitals contribute significantly to this demand, as intravenous access is critical for managing chronic kidney disease patients who require regular hemodialysis or peritoneal dialysis, with procedures demanding precise fluid management and continuous monitoring by skilled healthcare professionals. The rising prevalence of non communicable diseases such as cardiovascular disorders, diabetes, cancer, and renal failure globally has increased hospital admissions and the necessity for frequent intravenous interventions, reinforcing the dominance of this application segment. Hospitals and clinics possess the necessary infrastructure and trained personnel to handle advanced intravenous technologies including integrated closed systems, needleless connectors, AI enabled infusion pumps, and safety IV devices, which are often beyond the scope of smaller clinics or homecare settings. Safety IV devices are the largest technology segment in the global intravenous equipment market because they minimize needlestick injuries and reduce the risk of bloodborne infections, ensuring safer intravenous therapy for patients. Needlestick injuries have long been recognized as a serious risk in clinical settings, potentially exposing healthcare workers to infectious pathogens such as hepatitis B, hepatitis C, and HIV, which has driven hospitals, clinics, and homecare providers to adopt devices designed to reduce these risks. Regulatory mandates such as the Needlestick Safety and Prevention Act in the United States and similar guidelines issued by the European Union, World Health Organization, and other national health authorities require the use of engineered safety devices in medical procedures involving intravenous therapy, which has significantly fueled market adoption. Safety IV devices encompass a wide range of products including retractable needles, needleless connectors, and integrated closed systems, all designed to prevent accidental needle exposure during insertion, manipulation, and disposal. Hospitals, dialysis centers, and outpatient care facilities have increasingly implemented these devices to comply with regulatory requirements, protect staff, and enhance patient safety, making them a core element of intravenous therapy infrastructure. Technological advancements in the safety IV segment have enhanced device usability, reduced clinical errors, and improved patient comfort, with features such as automatic needle retraction, color coded connectors, and ergonomic designs that streamline workflow for nurses and clinicians. Moreover, the integration of safety devices with smart infusion systems and closed system technologies helps minimize contamination risk, reduce catheter associated infections, and support compliance with hospital infection control protocols.
to Download this information in a PDF
North America is the fastest growing region in the global intravenous equipment market due to advanced healthcare infrastructure and strong regulatory support for patient safety and infection control. The region is characterized by a large number of hospitals with sophisticated intensive care units, emergency departments, oncology centers, and dialysis facilities, all of which require continuous intravenous therapy for fluid management, medication administration, blood transfusions, and nutritional support. Technological advancement is a major growth factor, with the region leading in the development and adoption of smart infusion pumps, integrated closed systems, needleless connectors, and AI enabled monitoring devices, which improve workflow efficiency, enhance patient safety, and reduce medication errors. Regulatory frameworks enforced by authorities such as the US Food and Drug Administration and Health Canada ensure that intravenous devices meet stringent quality, performance, and safety standards, which drives healthcare providers to adopt advanced IV equipment confidently. Government policies and hospital initiatives focusing on infection prevention, needlestick injury reduction, and patient safety further accelerate the demand for safety IV devices, retractable needles, and closed system technologies, reinforcing North America’s leadership in the market. The aging population and rising prevalence of chronic diseases including cancer, cardiovascular disorders, diabetes, and renal failure contribute significantly to the demand for frequent and long term intravenous therapy, supporting sustained growth in the region. The trend toward homecare and outpatient IV therapy is particularly strong in North America, as patients and caregivers increasingly prefer treatment in home settings facilitated by portable infusion pumps and prefilled IV systems, which allow for continuous therapy outside hospital environments.
to Download this information in a PDF
• April 2025: BD launched the HemoSphere Alta platform with AI-driven decision support for critical-care hemodynamics. The platform integrates advanced predictive algorithms to anticipate hypotensive events, providing clinicians with real-time insights to improve patient outcomes and optimize workflow efficiency in intensive care and surgical settings. • April 2025: Teleflex secured FDA 510(k) clearance for the AC3 Range intra-aortic balloon pump. The transport-ready IABP supports critically ill cardiac patients during interfacility transfers, offering reliable counterpulsation therapy with enhanced mobility and flexible power options for ambulance and air transport environments. • April 2025: ICU Medical received FDA 510(k) clearance for its Plum Solo™ single channel IV pump, along with updated versions of its Plum Duo™ dual channel pump and LifeShield™ infusion safety software, officially launching its new IV Performance Platform. • March 2025: Merck’s subcutaneous pembrolizumab met non-inferiority versus IV dosing in a Phase 3 trial. The subcutaneous formulation demonstrated equivalent drug exposure and efficacy compared to intravenous administration, while significantly reducing administration time and improving patient convenience in oncology treatment settings. • December 2023: Baxter advances with the first intravenous (IV) Bag Recycling Pilot for U.S. hospitals. Pilot phase successfully demonstrated proof of concept, with more than six tons of plastic IV bag waste diverted from landfills at Northwestern Memorial Hospital. • October 2023: B. Braun Medical Inc. (B. Braun), a leader in smart infusion therapy, launched its new Introcan Safety 2 IV Catheter with Multi-Access Blood Control. IV access is a critical element of infusion therapy, and needlestick injuries continue to be a serious risk faced by clinicians in their daily routines, potentially exposing them to bloodborne pathogens. • August 2023: ICU Medical was granted FDA 510(k) clearance for its Plum Duo infusion pump together with LifeShield infusion safety software. The dual channel design allows the pump to deliver up to four compatible IV lines, helping in high-acuity setups or when multiple drugs need to be infused simultaneously. • June 2023: B. Braun launched its DoseTrac® Enterprise Infusion Management Software, a next generation platform that can link up to 40,000 infusion pumps across multiple facilities via a single central application. The software provides both real-time views and retrospective reporting, giving clinical and IT teams deep visibility into their entire pump fleet and medication usage. • April 2023: BD (Becton, Dickinson and Company), a leading global medical technology company, launched a new, easy-to-use advanced ultrasound device with a specialized probe designed to provide clinicians with optimal IV placement. The system features the BD Cue™ Needle Tracking System, offering a high-quality ultrasound image of the needle trajectory, and is compatible with BD Cue™ Needle Tracking-enabled catheters.
We are friendly and approachable, give us a call.